hotspot -WSS

hotspot

author：leisure time 2025-10-01 06:01:47 - browse：8273

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Can medical device makers keep up in the race to treat obesity?

explore

WSS

FDA approves first new drug developed for postpartum depression

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Disappointing trial forces Pfizer to pivot on obesity medicine plans

UnitedHealth’s Optum accused of antitrust violations in California

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Biden administration plans revamp of organ transplant system

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Sports medicine is finally prioritizing gender equality

Pediatric cancer treatments threatened by a new FDA policy

Medicare details structure of new drug price negotiation program

BIO selects John Crowley as new CEO

Activists slam private health insurers over coverage restrictions

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

State Dept. review finds Biden bears some blame for Afghanistan failures

What don’t we know about an Alzheimer’s drug side effect?

After affirmative action ruling, medical educators look to 'holistic review'

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

focus

Despite FDA concern, risk that CAR

CDC director unscathed in first congressional testimony

Senate panel passes drug pricing bills, but drops one PBM reform

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

J&J to emphasize cancer drugs, stop much of its vaccine research

explore

focus

focus

Wikipedia